Bareschino MA - Search Results

1

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.

Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Morgillo F, et al. Among authors: bareschino ma. Differentiation. 2007 Nov;75(9):788-99. doi: 10.1111/j.1432-0436.2007.00200.x. Epub 2007 Jul 2. Differentiation. 2007. PMID: 17608727 Review.

2

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.

Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciadiello F, Gridelli C. Sgambato A, et al. Among authors: bareschino ma. Curr Med Chem. 2012;19(20):3337-52. doi: 10.2174/092986712801215973. Curr Med Chem. 2012. PMID: 22664249 Review.

3

The role of antiangiogenetic agents in the treatment of breast cancer.

Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, Ciardiello F, Gridelli C. Bareschino MA, et al. Curr Med Chem. 2011;18(33):5022-32. doi: 10.2174/092986711797636072. Curr Med Chem. 2011. PMID: 22050750 Review.

4

Erlotinib in cancer treatment.

Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Bareschino MA, et al. Ann Oncol. 2007 Jun;18 Suppl 6:vi35-41. doi: 10.1093/annonc/mdm222. Ann Oncol. 2007. PMID: 17591829 Review.

5

The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.

Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F, Gridelli C. Schettino C, et al. Among authors: bareschino ma. Curr Genomics. 2008 Jun;9(4):252-62. doi: 10.2174/138920208784533665. Curr Genomics. 2008. PMID: 19452042 Free PMC article.

6

Combination of standard chemotherapy and targeted agents.

Bareschino MA, Morgillo F, Ciardiello F. Bareschino MA, et al. J Thorac Oncol. 2007 May;2(5 Suppl):S19-23. doi: 10.1097/01.JTO.0000268636.02709.b4. J Thorac Oncol. 2007. PMID: 17457224 Review. No abstract available.

7

New molecular targets in the treatment of NSCLC.

Schettino C, Bareschino MA, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato A, Gridelli C. Schettino C, et al. Among authors: bareschino ma. Curr Pharm Des. 2013;19(30):5333-43. doi: 10.2174/13816128113199990343. Curr Pharm Des. 2013. PMID: 23394083 Review.

8

The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.

Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciardiello F, Gridelli C. Sgambato A, et al. Among authors: bareschino ma. Curr Pharm Des. 2012;18(37):6155-68. doi: 10.2174/138161212803582478. Curr Pharm Des. 2012. PMID: 22873759 Review.

9

Non-small cell lung cancer therapy in the elderly.

Gridelli C, Rossi A, Maione P, Schettino C, Bareschino MA, Palazzolo G, Zeppa R, Ambrosio R, Barbato V, Sacco PC. Gridelli C, et al. Among authors: bareschino ma. Clin Adv Hematol Oncol. 2011 May;9(5):375-83. Clin Adv Hematol Oncol. 2011. PMID: 21685866

10

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.

Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R, Barbato V, Falanga M, Rossi A. Gridelli C, et al. Among authors: bareschino ma. Anticancer Res. 2010 Apr;30(4):1301-10. Anticancer Res. 2010. PMID: 20530444 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results